person · Reporting owner
Sanders Corazon (Corsee) D.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | Director | May 22, 2026 | May 27, 2026 |
| Calidi Biotherapeutics, Inc.CLDI · Entity 8408 | Director | August 17, 2026 | August 19, 2026 |
| Legend Biotech CorpLEGN · Entity 4033 | Director | September 29, 2026 | October 02, 2026 |
| Molecular Templates, Inc.MTEM · Entity 85987 | Director | September 27, 2024 | September 30, 2024 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | June 15, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date May 22, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-22 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-05-22 · Sale · Disposed 212 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 54,470 |
Reported balance
Holding disclosure · report date 2026-05-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 54,470 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
Calidi Biotherapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-08-17 | Direct | 6,000 |
Reported balance
After 2026-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 6,000 · Balance 6,000 F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F2: Does not include the stock options previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
F2: Does not include the stock options previously granted to the Reporting Person.
Legend Biotech Corp
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 52,731 |
Reported balance
After 2026-09-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-29 · Sale · Disposed 27,370 · Balance 52,731 F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
F2: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.
Molecular Templates, Inc.
Report date September 27, 2024 · Filed September 30, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2034-09-27 | Direct | 1,000 |
Reported balance
After 2024-09-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-27 · Grant · Acquired 1,000 · Balance 1,000 F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024.
Ultragenyx Pharmaceutical Inc.
Report date June 15, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,095 |
Reported balance
After 2026-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-15 · Sale · Disposed 2,000 · Balance 21,095 F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2026 Filed Oct 2, 2026 00:04 UTC | Legend Biotech Corp LEGN · Entity 4033 | SaleOrdinary Shares | 27,370 | $9.46 | $258,920.20 |
DisclosureSEC source: 0001796536-26-000010 · form4-10012026_081003.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,731 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 24, 2026 Filed Sep 28, 2026 20:10 UTC | Legend Biotech Corp LEGN · Entity 4033 | GrantOrdinary Shares | 20,986 | $0.00 | $0.00 |
DisclosureSEC source: 0001796536-26-000009 · form4-09282026_040901.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,101 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. F2 · shares: Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 23:00 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 6,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-26-039285 · ownership.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-08-17 F1 · security: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F1 · derivative.exercise_date: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan. F2 · balance_after: Does not include the stock options previously granted to the Reporting Person. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,000 | $25.05 | $50,100.00 |
DisclosureSEC source: 0001796536-26-000007 · ownership.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,095 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 22, 2026 Filed May 27, 2026 21:26 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 212 | $309.59 | $65,633.00 |
DisclosureSEC source: 0001796536-26-000005 · wk-form4_1779917164.xml · nonDerivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:38 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 14,058 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001796536-26-000004 · ownership.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,058 Underlying: Common Stock · 14,058 shares Expires 2036-05-14 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| May 14, 2026 Filed May 18, 2026 22:38 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 7,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001796536-26-000004 · ownership.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,095 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:57 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 34,151 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · derivative · entry 5 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,151 shares Expires 2034-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. F5 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:57 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 804 | $342.47 | $275,349.10 |
DisclosureSEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · nonDerivative · entry 4 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.42 to $342.675, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:57 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,823 | $340.20 | $620,185.33 |
DisclosureSEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · nonDerivative · entry 3 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 804 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.04 to $340.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:57 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 2,627 | $159.03 | $417,771.81 |
DisclosureSEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · nonDerivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 21:31 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 34,645 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-25-000139 · wk-form4_1757453510.xml · derivative · entry 4 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,645 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 21:31 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 2,665 | $337.00 | $898,105.00 |
DisclosureSEC source: 0001651308-25-000139 · wk-form4_1757453510.xml · nonDerivative · entry 3 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 21:31 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 2,665 | $155.68 | $414,887.20 |
DisclosureSEC source: 0001651308-25-000139 · wk-form4_1757453510.xml · nonDerivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 17:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,405 | $37.39 | $89,922.95 |
DisclosureSEC source: 0000950170-25-088878 · ownership.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,344 Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $18.19 | $0.00 |
DisclosureSEC source: 0001651308-25-000086 · wk-form4_1747957367.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,750 Underlying: Ordinary Shares · 22,750 shares Expires 2035-05-20 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 21, 2025 Filed May 22, 2025 23:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 10,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000086 · wk-form4_1747957367.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,226 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:33 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 10,787 | $0.00 Strike: $34.84 | $0.00 |
DisclosureSEC source: 0000950170-25-074666 · ownership.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Common Stock · 10,787 shares Expires 2035-05-15 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:33 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,740 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074666 · ownership.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,749 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026. Read SEC document |
| September 27, 2024 Filed Sep 30, 2024 17:35 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-24-110454 · ownership.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2034-09-27 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 18:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 584 | $40.98 | $23,932.32 |
DisclosureSEC source: 0000950170-24-081302 · ownership.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,009 Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 9,900 | $0.00 Strike: $37.42 | $0.00 |
DisclosureSEC source: 0000950170-24-075485 · ownership.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 18:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,345 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-075485 · ownership.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,593 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 23:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,737 | $41.10 | $71,390.70 |
DisclosureSEC source: 0000950170-24-071548 · ownership.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,248 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:55 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,151 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000057 · wk-form4_1717793720.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,151 Underlying: Ordinary Shares · 34,151 shares Expires 2034-06-04 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:55 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000057 · wk-form4_1717793720.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,241 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 18:46 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001171843-23-006569 · ownership.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2033-10-27 F1 · date: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023. F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of October 27, 2023. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 18:34 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 585 | $46.76 | $27,354.60 |
DisclosureSEC source: 0001209191-23-040269 · doc4.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,985 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:21 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 478 | $182.65 | $87,307.42 |
DisclosureSEC source: 0001651308-23-000101 · wf-form4_168790086732122.xml · nonDerivative · entry 3 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.34 to $183.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 21:21 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $180.74 | $18,074.00 |
DisclosureSEC source: 0001651308-23-000101 · wf-form4_168790086732122.xml · nonDerivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:08 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 26,975 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001651308-23-000099 · wf-form4_168730246724090.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,975 Underlying: Ordinary Shares · 26,975 shares Expires 2033-06-14 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:08 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 12,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-23-000099 · wf-form4_168730246724090.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,414 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 18:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,485 | $51.65 | $76,700.25 |
DisclosureSEC source: 0001209191-23-035690 · doc4.xml · nonDerivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,570 F2 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,110 | $0.00 Strike: $51.82 | $0.00 |
DisclosureSEC source: 0001209191-23-035690 · doc4.xml · derivative · entry 3 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires 2033-06-07 F3 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 18:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035690 · doc4.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,055 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024. Read SEC document |
| June 24, 2022 Filed Jun 29, 2022 19:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 6,245 | $0.00 Strike: $60.57 | $0.00 |
DisclosureSEC source: 0001209191-22-039770 · doc4.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,245 Underlying: Common Stock · 6,245 shares Expires 2032-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 24, 2022 Filed Jun 29, 2022 19:48 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039770 · doc4.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,195 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,645 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000105 · wf-form4_165610664484850.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,645 Underlying: Ordinary Shares · 34,645 shares Expires 2032-06-21 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000105 · wf-form4_165610664484850.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,492 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 16:15 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0000899243-22-021187 · doc4.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2023. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 23:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,255 | $0.00 Strike: $96.29 | $0.00 |
DisclosureSEC source: 0001209191-21-044165 · doc4.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,255 Underlying: Common Stock · 7,255 shares Expires 2031-06-29 F2 · derivative.exercise_date: The option shall vest with respect to 1/36th of the shares monthly such that the option shall fully vest on the third anniversary of the grant date. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 23:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044165 · doc4.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,895 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/3rd of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the third anniversary of the grant date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000120 · wf-form4_162430771425098.xml · derivative · entry 2 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000120 · wf-form4_162430771425098.xml · nonDerivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 16:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0000899243-21-022044 · doc4.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2022. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 20:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 27,482 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001651308-20-000141 · wf-form4_159847508819916.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,482 Underlying: Ordinary Shares · 27,482 shares Expires 2030-08-23 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 17:05 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0000899243-20-014734 · doc4.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-28 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 28, 2021 Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 08:05 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0000899243-19-029722 · doc4.xml · derivative · entry 1 Sanders Corazon (Corsee) D. · CIK 0001796536 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: 50% of the total number of shares subject to the option shall vest on December 19, 2020 and the remaining 50% shall vest on December 19, 2021, subject to the reporting person's continuous service with Molecular Templates, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.